Tyrosine kinase inhibition has proved to be a promising strategy to support cancer therapy against non-small cell lung carcinoma (EGFR inhibitors) and leukemic malignancies (CML: ABL inhibitors; AML: FLT3 inhibitors; ALL: ABL inhibitors). This evidence concerns the gene EGFR and non-small cell lung carcinoma.